{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-028296","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.529387+00:00","generated_at":"2026-06-09T23:07:28.002086+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Omeros Phase 3 ARTEMIS-IGAN trial fails primary endpoint; narsoplimab BLA in IgAN discontinued","bullets":["Narsoplimab did not achieve statistically significant reduction in proteinuria at 36 weeks vs placebo (24-hour UPE >2 g/day).","Placebo group showed markedly greater proteinuria reduction than in other IgA nephropathy trials.","Company will not submit BLA for narsoplimab in IgAN and is discontinuing the ARTEMIS-IGAN trial.","Funds redirected to OMS906 (alternative pathway inhibitor) Phase 2/3 programs and narsoplimab BLA resubmission for HSCT-TMA.","Narsoplimab was generally well tolerated with no new safety concerns."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-028296","json":"https://secwatch.observer/filing/0001437749-23-028296.json","markdown":"https://secwatch.observer/filing/0001437749-23-028296.md","text":"https://secwatch.observer/filing/0001437749-23-028296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923028296/0001437749-23-028296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774923028296/omer20231012c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:07:28.002086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}